Healthcare M&A » By The Online Investor Staff, updated Thu., Apr. 18, 11:42 PM
Recent mergers and acquisitions in the Healthcare M&A category.
| This Slide: #42 of 100 |
Slide #42. TetraLogic Pharmaceuticals Corporation — Shape Pharmaceuticals, Inc.
Acquirer:
TetraLogic Pharmaceuticals Corporation (TLOG)
Acquiree:
Shape Pharmaceuticals, Inc.
Details:
TetraLogic Pharmaceuticals Corporation (Nasdaq:TLOG) announced today that it has executed a definitive agreement to acquire by merger 100% of Shape Pharmaceuticals, a privately-held biotechnology company developing suberohydroxamic acid phenyl ester (SHAPE), a novel, tissue-targeted HDAC inhibitor in a topical gel formulation to treat stage IA-IIA Cutaneous T-Cell Lymphoma (CTCL), adding a second clinical-stage oncology compound to the TetraLogic portfolio.
TetraLogic Pharmaceuticals is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics in oncology, infectious diseases and autoimmune diseases. Co. has two clinical-stage product candidates in development: birinapant and suberohydroxamic acid 4-methoxycarbonyl phenyl ester (SHAPE). SHAPE is Co.'s proprietary histone deacetylase inhibitor that it is developing for topical use for the treatment of early-stage cutaneous T-cell lymphoma. Birinapant is a small molecule therapeutic that mimics Second Mitochondrial Activator of Caspases, which causes apoptosis, or cell-death, in damaged cells.
Open the TLOG Page at The Online Investor »
|
|||||||||
Open the TLOG Page at The Online Investor (in a new window) »
 Free TLOG Email Alerts:
Get SEC Filing Alerts Get Dividend Alerts 
|
Avg. Broker Rec.
|
Strong Buy (4.00 out of 4) 100th percentile
(ranked higher than approx. 100% of all stocks covered)
Based on Zacks ABR data; powered by Xignite |
